MHC II− tumor cells, suggesting that LAG-3–expressing TILs may be preferentially located in proximity to MHC II+ tumor cells, allowing for LAG-3 activation and the inhibition of antitumor immunity83. The gene discussed is LAG3; the disease is neoplasm.